Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of the whole industry chain, announced the acceptance of supplemental biologics license application by China National Medical Products Administration (NMPA) for JUNMAIKANG^® (Adalimumab), developed by Mabwell in cooperation with Junshi Biosciences (1877.HK, 688180.SH), for the treatment of Crohn's disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, and pediatric Crohn's disease.

JUNMAIKANG^® has received support from the Major Scientific and Technological Special Project for Significant New Drug Development during China’s Twelfth Five-year Plan Period, and was approved for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis in March of this year. In accordance with the supplementary agreement, and sales and promotional services agreement concluded, Mabwell is responsible for the promotion of JUNMAIKANG^®, and will be responsible for its production after the completion of the production transfer. The profits will be distributed by Mabwell or Mabwell's subsidiary and Junshi Biosciences at 50%:50%.